Gvoke VialDx is a concentrated liquid glucagon product. For diagnostic procedures, it works as a gastrointestinal motility inhibitor. The product is supplied as a single-dose vial containing 1mg of ...
Holdings announced that its supplemental new drug application, sNDA, of Gvoke VialDx has received U.S Food and Drug ...
Xeris Biopharma Holdings has received regulatory approval for a new use of its Gvoke liquid glucagon in gastrointestinal ...
Zacks.com on MSN3d
Strength Seen in Xeris Biopharma (XERS): Can Its 5.6% Jump Turn into More Strength?Xeris Biopharma (XERS) witnessed a jump in share price last session on above-average trading volume. The latest trend in ...
Xeris also announced it has partnered with American Regent to commercialize Gvoke VialDx. Under the terms of the agreement, Xeris will be responsible for product supply, and American Regent will ...
InvestingPro analysis reveals 8 additional key insights about the company’s potential. Gvoke VialDx™ is designed to temporarily inhibit gastrointestinal movement during diagnostic procedures ...
Just in, Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) has received approval for its supplemental new drug application (sNDA) of Gvoke VialDx™ from the U.S. Food and Drug Administration (FDA).
Earlier this week, the FDA approved Xeris’ supplemental new drug application for Gvoke VialDx for use as a diagnostic aid, designed to temporarily inhibit movement of the gastrointestinal tract ...
CHICAGO - Xeris Biopharma Holdings, Inc. (NASDAQ: XERS), a $742 million market cap pharmaceutical company whose stock has surged 116% over the past year, has announced the FDA approval of its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback